|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-10-2
|
|
pubmed:abstractText |
Infliximab is an effective treatment for refractory or fistulizing Crohn's disease (CD). However, about 30% of patients do not respond to infliximab for unknown reasons. Identifying predictive factors of response is important for optimizing clinical management and for better understanding infliximab's mechanisms of action. The aim of this study was to assess whether demographic or clinical parameters influence short-term response to infliximab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
pubmed-author:BelaicheJacquesJ,
pubmed-author:Belgian Group of Infliximab Expanded Access Program in Crohn's Disease,
pubmed-author:CarbonezAnA,
pubmed-author:D'HaensGeertG,
pubmed-author:De VosMartineM,
pubmed-author:FiasseReneR,
pubmed-author:LouisEdouardE,
pubmed-author:NomanMajaM,
pubmed-author:PelckmansPaulP,
pubmed-author:PescatorePaulP,
pubmed-author:ReynaertHendrikH,
pubmed-author:RutgeertsPaulP,
pubmed-author:Van AsscheGertG,
pubmed-author:Van GossumAndreA,
pubmed-author:VermeireSeverineS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2357-63
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12358256-Adult,
pubmed-meshheading:12358256-Antibodies, Monoclonal,
pubmed-meshheading:12358256-Cohort Studies,
pubmed-meshheading:12358256-Crohn Disease,
pubmed-meshheading:12358256-Demography,
pubmed-meshheading:12358256-Dose-Response Relationship, Drug,
pubmed-meshheading:12358256-Female,
pubmed-meshheading:12358256-Gastrointestinal Agents,
pubmed-meshheading:12358256-Humans,
pubmed-meshheading:12358256-Male,
pubmed-meshheading:12358256-Middle Aged,
pubmed-meshheading:12358256-Outcome Assessment (Health Care),
pubmed-meshheading:12358256-Predictive Value of Tests,
pubmed-meshheading:12358256-Time Factors,
pubmed-meshheading:12358256-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
|
|
pubmed:affiliation |
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
